Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

Original reporting
Published Jun 3, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 11:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore — source image
Decision brief

The 30-second read

$SUJABullishMed
01

Why it matters

The immediate tradable element is the rating upgrade and the clustering of bullish initiations/targets, which can tighten perceived downside and attract momentum/quality screens.

02

Market read

For traders, this is a sentiment/positioning catalyst rather than a fundamental disclosure; expect the strongest impact around the upgrade dissemination window.

03

What to watch

Price action may be more influenced by liquidity/flow and any upcoming company-specific catalysts than by target-price changes alone.

Relevance 7/10Novelty 6/10Timing: today/this week as the upgrade hits analyst coverage and may affect trading sentiment immediately

Background

The piece summarizes a research note cycle: Evercore upgraded SUJA to strong-buy, while other firms initiated coverage with buy/outperform ratings and targets.

Company-level read

Ticker impact

$SUJABullishMedium confidence
Context

Evercore upgraded Suja Life to a “strong-buy,” adding fresh analyst conviction and potentially shifting near-term sentiment and positioning.

Expected impact

Mild-to-moderate upside bias over days as traders react to the upgrade; follow-through depends on broader tape and any new fundamental catalysts.

Evidence & confidence

The article provides a specific rating change (Evercore strong-buy) plus multiple other initiations/targets, but no new company fundamentals (earnings, guidance, contracts).

Market effects

Limited; this is single-name analyst coverage rather than a sector-wide fundamental shift.

None indicated beyond US small/mid-cap sentiment.

None indicated.

Counterpoint

If the upgrade is not tied to new fundamentals, the stock may fade after the initial analyst-driven reaction.

Key entities

  • Suja Life

    NASDAQ-listed packaged food company covered by Evercore and other analysts in the article.

  • Evercore

    Upgraded SUJA to a “strong-buy” rating in a Monday research report.

Related articles

$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

$SUJAMed

SUJA LIFE, INC. (SUJA): Results of Operations and Financial Condition

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sujalifeq22026earningsrele.htm EX-99.1 Document Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,

$SUJAMedAI 9/10

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

$NVDAMed

Nvidia says it’s raising some prices more than 15%

Nvidia plans to raise prices for AI chip servers by over 15% due to rising memory costs, according to Bloomberg. The company is also investing $6 billion to license AI technology from startup Poolside, competing with firms like OpenAI and Anthropic. Anthropic faces pressure as customers opt for cheaper AI models ahead of its potential IPO.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.